[go: up one dir, main page]

PE20081490A1 - N-(4-(2-amino-3-cloropiridin-4-iloxi)-3-fluorofenil)-4-etoxi-1-(4-fluorofenil)-2-oxo-1,2-dihidropiridina-3-carboxamida y una composicion farmaceutica - Google Patents

N-(4-(2-amino-3-cloropiridin-4-iloxi)-3-fluorofenil)-4-etoxi-1-(4-fluorofenil)-2-oxo-1,2-dihidropiridina-3-carboxamida y una composicion farmaceutica

Info

Publication number
PE20081490A1
PE20081490A1 PE2007001538A PE2007001538A PE20081490A1 PE 20081490 A1 PE20081490 A1 PE 20081490A1 PE 2007001538 A PE2007001538 A PE 2007001538A PE 2007001538 A PE2007001538 A PE 2007001538A PE 20081490 A1 PE20081490 A1 PE 20081490A1
Authority
PE
Peru
Prior art keywords
fluorophenyl
iloxi
etoxy
chloropyridin
dihydropyridine
Prior art date
Application number
PE2007001538A
Other languages
English (en)
Inventor
Robert M Borzilleri
Gretchen M Schroeder
Zhen-Wei Cai
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20081490A1 publication Critical patent/PE20081490A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA CANTIDAD EFECTIVA DEL COMPUESTO N-(4-(2-AMINO-3-CLOROPIRIDIN-4-ILOXI)-3-FLUOROFENIL)-4-ETOXI-1-(4-FLUOROFENIL)-2-OXO-1,2-DIHIDROPIRIDINA-3-CARBOXAMIDA, EN UN PORTADOR QUE COMPRENDE CELULOSA MICROCRISTALINA Y MANITOL O LACTOSA Y ADEMAS COMPRENDE UN AGENTE LUBRICANTE Y DESINTEGRANTE, SIENDO UTIL EN EL TRATAMIENTO DEL CANCER DEPENDIENTE DE LA ACTIVACION DE Met REGULADA POR LA AMPLIFICACION DEL GEN, UNA MUTACION Met ACTIVADA Y/O ESTIMULACION HGF
PE2007001538A 2006-11-08 2007-11-08 N-(4-(2-amino-3-cloropiridin-4-iloxi)-3-fluorofenil)-4-etoxi-1-(4-fluorofenil)-2-oxo-1,2-dihidropiridina-3-carboxamida y una composicion farmaceutica PE20081490A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85754006P 2006-11-08 2006-11-08

Publications (1)

Publication Number Publication Date
PE20081490A1 true PE20081490A1 (es) 2008-10-30

Family

ID=39048786

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001538A PE20081490A1 (es) 2006-11-08 2007-11-08 N-(4-(2-amino-3-cloropiridin-4-iloxi)-3-fluorofenil)-4-etoxi-1-(4-fluorofenil)-2-oxo-1,2-dihidropiridina-3-carboxamida y una composicion farmaceutica

Country Status (20)

Country Link
US (2) US7851489B2 (es)
EP (1) EP2089364B1 (es)
JP (1) JP5276005B2 (es)
KR (1) KR101390076B1 (es)
CN (1) CN101535264B (es)
AR (1) AR063628A1 (es)
AU (1) AU2007317296B2 (es)
CA (1) CA2669266C (es)
CL (1) CL2007003226A1 (es)
DK (1) DK2089364T3 (es)
ES (1) ES2424851T3 (es)
HR (1) HRP20130626T1 (es)
MX (1) MX2009004699A (es)
NO (1) NO342395B1 (es)
PE (1) PE20081490A1 (es)
PL (1) PL2089364T3 (es)
PT (1) PT2089364E (es)
SI (1) SI2089364T1 (es)
TW (1) TWI409259B (es)
WO (1) WO2008058229A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101608096B1 (ko) 2008-01-23 2016-03-31 브리스톨-마이어스 스큅 컴퍼니 ４-피리디논 화합물 및 암을 위한 그의 용도
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
EP2563773A1 (en) 2010-04-29 2013-03-06 Deciphera Pharmaceuticals, LLC Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
JP5820874B2 (ja) * 2010-04-30 2015-11-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｎ−（４−（２−アミノ−３−クロロピリジン−４−イルオキシ）−３−フルオロフェニル）−４−エトキシ−１−（４−フルオロフェニル）−２−オキソ−１，２−ジヒドロピリジン−３−カルボキサミドを含有する医薬組成物
CN102241625B (zh) * 2010-05-13 2014-10-29 中南大学 1-(取代芳基)-5-((取代芳胺基)甲基)吡啶-2(1h)酮化合物、制备方法及其用途
CN102070518B (zh) * 2011-01-24 2012-05-02 江苏先声药物研究有限公司 取代吡啶及氮杂吲哚衍生物的合成
KR20140007954A (ko) * 2011-06-10 2014-01-20 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
SG11201402531XA (en) * 2011-11-22 2014-08-28 Deciphera Pharmaceuticals Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
ES2634414T3 (es) 2012-07-28 2017-09-27 Calitor Sciences, Llc Compuestos de pirazolona sustituida y métodos de uso
US8975282B2 (en) 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
SI3394033T1 (sl) 2015-12-22 2021-03-31 Incyte Corporation Heterociklične spojine kot imunomodulatorji
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MA45116A (fr) 2016-05-26 2021-06-02 Incyte Corp Composés hétérocycliques comme immunomodulateurs
ES2927984T3 (es) 2016-06-20 2022-11-14 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2930092T3 (es) * 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018116139A1 (en) * 2016-12-19 2018-06-28 Novartis Ag New picolinic acid derivatives and their use as intermediates
MX391981B (es) 2016-12-22 2025-03-21 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018136010A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
TW201834649A (zh) 2017-03-02 2018-10-01 新加坡商亞獅康私人有限公司 癌症療法
CN108623568B (zh) * 2017-03-21 2022-04-19 南京汇诚制药有限公司 9,10二氢菲类丙型肝炎病毒抑制剂的盐型及其制备
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2019083456A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER FOR NORMALIZING ANGIOGENESIS IN A CANCER MASS
WO2019083458A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR THE TREATMENT OF CANCER TO REDUCE HYPOXIA
WO2019083455A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS PRESENTING HER1, HER2 AND / OR HER3-ACTIVATED HERC-RECEPTOR CANCER CELLS
WO2019083457A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS MUTATION OF THE BETA-CATENIN PATHWAY
US11623923B2 (en) * 2017-11-24 2023-04-11 Medshine Discovery, Inc. Uracil compound as c-MET/AXL inhibitor
CN111295386B (zh) 2018-03-08 2022-09-06 伟迈可生物有限公司 噻吩并吡啶衍生物及含有该衍生物的药物组合物
SMT202300065T1 (it) 2018-03-30 2023-05-12 Incyte Corp Composti eterociclici come immunomodulatori
PL3790877T3 (pl) 2018-05-11 2023-06-12 Incyte Corporation Pochodne tetrahydroimidazo[4,5-c]pirydyny jako immunomodulatory pd-l1
US20210379070A1 (en) 2018-10-09 2021-12-09 Aslan Pharmaceuticals Pte Ltd Malonate salt of varlitinib
EP3867229A4 (en) * 2018-10-19 2022-07-27 The University Of British Columbia TOPOISOMERASE II CATALYTIC INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES
US20220119425A1 (en) * 2019-01-15 2022-04-21 The Translational Genomics Research Institute Phosphonate conjugates and uses thereof
EP4011885A4 (en) 2019-08-02 2023-01-18 Wellmarker Bio Co., Ltd. CONDENSED CYCLE OXO-PYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
KR20220059386A (ko) 2019-09-06 2022-05-10 웰마커바이오 주식회사 바이오마커 기반 치료용 조성물
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrimido[3,2–D]pyrimidine compounds as immunomodulators
CN114829366A (zh) 2019-11-11 2022-07-29 因赛特公司 Pd-1/pd-l1抑制剂的盐及结晶形式
CN115003307A (zh) 2020-02-06 2022-09-02 伟迈可生物有限公司 用于预防或治疗与kras突变相关的癌症的药物组合物
KR20210111711A (ko) 2020-03-03 2021-09-13 웰마커바이오 주식회사 Kras 돌연변이 및 활성화된 ron이 존재하는 암의 예방 또는 치료용 약학 조성물
KR20210142554A (ko) 2020-05-18 2021-11-25 웰마커바이오 주식회사 Ron 돌연변이와 관련된 비소세포 폐암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법
KR20210142555A (ko) 2020-05-18 2021-11-25 웰마커바이오 주식회사 Ron 돌연변이와 관련된 췌장암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법
KR20210142553A (ko) 2020-05-18 2021-11-25 웰마커바이오 주식회사 Ron 돌연변이와 관련된 소세포 폐암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
KR20220111673A (ko) * 2021-02-02 2022-08-09 주식회사 엘지화학 단백질 키나아제 억제제로서의 신규한 화합물
CN117355533A (zh) * 2021-06-22 2024-01-05 株式会社Lg化学 作为蛋白激酶抑制剂的新型化合物
US20230257364A1 (en) * 2022-02-16 2023-08-17 Cmg Pharmaceutical Co., Ltd. Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof
JP2026500409A (ja) * 2022-12-23 2026-01-06 エルジー・ケム・リミテッド Ｒｏｎ阻害剤としての新規な化合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430885A3 (en) 1989-12-01 1991-11-06 Ciba-Geigy Ag Anthelmintical compounds
US6143764A (en) 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
CA2333554A1 (en) 1998-06-17 1999-12-23 Chu-Baio Xue Cyclic hydroxamic acids as metalloproteinase inhibitors
US6355660B1 (en) 1999-07-20 2002-03-12 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
JP2003528806A (ja) 1999-07-20 2003-09-30 ダウ・アグロサイエンス・エル・エル・シー 殺菌・殺カビ性複素環式芳香族アミドおよびそれらの組成物、使用および製造方法
IL148576A0 (en) 1999-09-21 2002-09-12 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
FR2812633A1 (fr) 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
SE0102384D0 (sv) 2001-07-03 2001-07-03 Pharmacia Ab New compounds
JP2005510564A (ja) 2001-11-28 2005-04-21 藤沢薬品工業株式会社 アポリポタンパク質ｂ阻害剤としての複素環式アミド化合物
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
JP2005263787A (ja) 2004-02-17 2005-09-29 Ishihara Sangyo Kaisha Ltd アミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
WO2005113494A2 (en) 2004-05-07 2005-12-01 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2007033196A1 (en) 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
KR101390076B1 (ko) 2014-04-29
HRP20130626T1 (en) 2013-08-31
WO2008058229A1 (en) 2008-05-15
PT2089364E (pt) 2013-08-26
CL2007003226A1 (es) 2008-02-08
TWI409259B (zh) 2013-09-21
HK1131608A1 (en) 2010-01-29
AR063628A1 (es) 2009-02-04
NO20091605L (no) 2009-05-27
CN101535264A (zh) 2009-09-16
PL2089364T3 (pl) 2013-11-29
US7851489B2 (en) 2010-12-14
JP2010509362A (ja) 2010-03-25
US20080114033A1 (en) 2008-05-15
US20110052583A1 (en) 2011-03-03
EP2089364A1 (en) 2009-08-19
EP2089364B1 (en) 2013-06-12
NO342395B1 (no) 2018-05-14
ES2424851T3 (es) 2013-10-09
DK2089364T3 (da) 2013-09-02
AU2007317296A1 (en) 2008-05-15
CA2669266A1 (en) 2008-05-15
JP5276005B2 (ja) 2013-08-28
KR20090096423A (ko) 2009-09-10
AU2007317296B2 (en) 2012-07-05
US8536200B2 (en) 2013-09-17
SI2089364T1 (sl) 2013-10-30
TW200829564A (en) 2008-07-16
CA2669266C (en) 2014-04-29
MX2009004699A (es) 2009-05-15
CN101535264B (zh) 2012-11-28

Similar Documents

Publication Publication Date Title
PE20081490A1 (es) N-(4-(2-amino-3-cloropiridin-4-iloxi)-3-fluorofenil)-4-etoxi-1-(4-fluorofenil)-2-oxo-1,2-dihidropiridina-3-carboxamida y una composicion farmaceutica
EA201290041A1 (ru) Лечение расстройств, связанных с макрофагами
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
MY165570A (en) Inhibitors of poly (adp-ribose) polymerase
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
CR11723A (es) Agente para tratar enfermedad
NZ604031A (en) Methods of treatment of pancreatic cancer
GB2467670A (en) Chemical entities and therapeutic uses thereof
EP2349279A4 (en) MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
NZ716421A (en) Drug for treatment of nonalcoholic fatty liver disease
ATE439140T1 (de) Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen
WO2013024282A3 (en) Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer
MX377802B (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
DK1656122T4 (da) Transdermale lægemiddeltilberedninger med kombinationer af aktive stoffer til behandling af Parkinsons syge
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
DOP2004000907A (es) Procedimientos y composiciones farmaceuticas para tratar aterosclerosis dislipidemias y afecciones relacionadas
CL2011000877A1 (es) Composicion inmunogena para el tratamiento y/o profilaxis de ganado contra infecciones microbiologicas porque comprende antigeno de mycoplasma bovis; metodo de coadministracion de dos o mas antigenos a un ganado bovino.
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
ATE448777T1 (de) Mittel für die transdermale verabreichung von nikotin
PE20140255A1 (es) Tableta dispersable en forma oral
MA32544B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio

Legal Events

Date Code Title Description
FG Grant, registration